AFIP |
Armed Forces Institute of Pathology |
CSF1R |
macrophage colony-stimulating-factor 1 receptor |
CTLA4 |
cytotoxic T-lymphocyte-associated antigen 4 |
DFS |
disease-free survival |
EGJ |
esophagogastric junction |
EMR |
endoscopic mucosal resection |
ESD |
endoscopic submucosal dissection |
ESEG |
European Society of Gastrointestinal Endoscopy |
ESMO |
European Society for Medical Oncology |
EUS |
endoscopic ultrasonography |
EUS-FNA |
EUS-guided fine needle aspiration |
FDA |
Food and Drug Administration |
FLT3 |
FMS-like tyrosine kinase 3 |
GI tract |
gastrointestinal tract |
GIST |
gastrointestinal stromal tumor |
GPR20 |
G protein-coupled receptor 20 |
HIF-1α |
hypoxia-inducible factor-1α |
HR |
hazard ratio |
IGF1R |
insulin growth factor-1 receptor |
IHC |
immunohistochemistry |
IMT |
inflammatory myofibroblastic tumor |
LECS |
laparoscopic endoscopic cooperative surgery |
MIAB |
mucosal incision-assisted biopsy |
NCCN |
National Comprehensive Cancer Network |
NIH |
National Institutes of Health |
OS |
overall survival |
PD-1 |
programmed death-1 |
PD-L1 |
programmed death-ligand 1 |
PEComa |
perivascular epithelioid cell tumor |
PFS |
progression-free survival |
RFS |
recurrence-free survival |
ROSE |
rapid on-site evaluation |
RR |
response rate |
RTK |
receptor tyrosine kinase |
SDH |
succinate dehydrogenase |
SFT |
solitary fibrous tumor |
SMT |
submucosal tumor |
TKI |
tyrosine kinase inhibitors |
Tx |
therapy |
VEGFR |
vascular endothelial growth factor receptor |
SSTR2 |
somatostatin receptor 2 |